Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

Nektar confirms BMS deal for NKTR-214 is on track

Nektar confirms BMS deal for NKTR-214 is on track

Robin said that studies are now underway or planned for the CD122-biased agonist in small cell lung cancer (SCLC), breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer (TNBC) ... Combination trials in head and neck cancer and

Latest news

  • Sanofi and Regeneron re-jig immuno-oncology deal Sanofi and Regeneron re-jig immuno-oncology deal

    That candidate is currently in trials for ovarian cancer, but it has potential in cancers expressing the MUC16 biomarker is also frequently expressed in lung, pancreatic, gastric and colorectal cancer.

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    China looks set to be a big market for the drug in its own right, however, as CRC is the second-most common form of cancer with an estimated 380, 000 ... alongside AZ’s EGFR inhibitor Iressa (gefitinib), as well as gastric cancer.

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    cancer (NSCLC), hepatocellular carcinoma, and oesophageal squamous cell carcinoma, the company is developing BTK inhibitor zanubrutinib and pamiparib, a PARP 1/2 inhibitor. ... Meanwhile, pamiparib is being developed for solid tumours, and last month

More from news
Approximately 3 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... access to its lead candidate FS102 for HER-2 positive patients in breast and gastric cancer.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing agreement for Europe and Japan. ... 100+. ACT Biotech/ Eddingpharm. Acquisition. Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics